Trial Profile
Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Interferon alpha-2b (Primary) ; Pembrolizumab (Primary) ; Rintatolimod (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 30 Jan 2024 Planned initiation date (estimated date of first participant enrollment) changed from 30 Dec 2023 to 28 Feb 2024.
- 30 Jan 2024 Status changed from not yet recruiting to recruiting.
- 30 Oct 2023 Planned End Date changed from 30 Jun 2025 to 30 Dec 2025.